Clinical trials: Temozolomide, completed
Glioblastoma Multiforme
The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma
This clinical trial is testing the safety, tolerability and effectiveness of NVX-108 administered via intravenous infusion in combination with standard radiation and chemotherapy.
- Trial name
- GBM (NCT02189109)
- Testing
- NVX-108
- Where
- 4 sites in Australia
- Volunteers
- 11 people
- Sponsor
- NuvOx LLC
Glioblastoma Multiforme
Safety and Efficacy of Talampanel in Glioblastoma Multiforme
The purpose of this study is to estimate overall survival for adult patients with newly diagnosed glioblastoma multiforme treated with talampanel during radiation therapy with concurrent and adjuvant temozolomide.
- Trial name
- NCT00267592
- Testing
- Talampanel, Radiation Therapy (RT) 5 days a week +, temozolomide(TMZ) 75mg
- Volunteers
- 72 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Recurrent Central Nervous System Neoplasm
Temozolomide in Treating Patients With Recurrent High-Grade Glioma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00619112
- Testing
- temozolomide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, San Francisco
Malignant Glioma
18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy
This phase II trial studies how well fluorine F 18 fluorodopa (18F-DOPA)-positron emission tomography (PET) works in finding tumors in patients with newly diagnosed gliomas undergoing radiation therapy.
- Trial name
- NCT01991977
- Testing
- Diffusion Weighted Imaging, Fluorine F 18 Fluorodopa, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Mayo Clinic
Melanoma
Randomised Study to Compare the Efficacy of AZD6244 vs TMZ
The primary purpose of this study is to compare the efficacy of AZD6244 (ARRY-142886) with temozolomide in patients with advanced melanoma
- Trial name
- NCT00338130
- Testing
- AZD6244, Temozolomide
- Where
- 33 sites in United States, Argentina and 8 more
- Volunteers
- 239 people
- Sponsor
- AstraZeneca
Glioma
Hypofractionated IMRT With Temozolomide for HGG
To evaluate safety and feasibility of hypofractionated IMRT in addition to chemotherapy, concomitant and adjuvant, in patients with newly diagnosed HGGs after surgery.
- Trial name
- NCT02082119
- Testing
- Hypofractionated IMRT
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- Istituto Clinico Humanitas
Brain and Central Nervous System Tumors, Lymphoma
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00416819
- Testing
- filgrastim, rituximab, cytarabine
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Glioblastoma Multiforme (Grade IV) of Cerebellum
Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma
This multicenter, open-label, phase Ib trial aims to assess the safety and activity and safety of crizotinib (in combination with radiotherapy and temozolomide) in adult patients with newly diagnosed glioblastoma.
- Trial name
- NCT02270034
- Testing
- Crizotinib
- Where
- 4 sites in Spain
- Volunteers
- 38 people
- Sponsor
- Grupo Español de Investigación en Neurooncología
Brain and Central Nervous System Tumors
Radiation Therapy or Temozolomide in Treating Patients With Gliomas
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00182819
- Testing
- temozolomide, radiation therapy
- Where
- 89 sites in Australia, Austria and 17 more
- Volunteers
- 709 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Malignant Melanoma
Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
The primary goal of this study is to determine if people with metastatic melanoma who receive Heat Shock Protein-Peptide Complex - 96 (HSPPC-96 or Oncophage) after surgery live longer than people who may or may not have surgery…
- Trial name
- NCT00039000
- Testing
- HSPPC-96 or Oncophage
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 350 people
- Sponsor
- Agenus Inc.
Metastatic Colorectal Cancer
Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients
Open-label, randomized, multicenter, Phase II trial designed to estimate the efficacy of CAPTEM versus FOLFIRI as second line treatment in MGMT methylated, RAS mutated advanced CRC patients who have progressed on or after…
- Trial name
- CAPTEM (NCT02414009)
- Testing
- Capecitabine, Temozolomide, Irinotecan
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Glioblastoma
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients with newly diagnosed glioblastoma receiving concurrent radiation and temozolomide.
- Trial name
- NCT05635734
- Testing
- Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg
- Where
- 4 sites in Spain
- Volunteers
- 33 people
- Sponsor
- Cantex Pharmaceuticals
Brain and Central Nervous System Tumors
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating adults with newly diagnosed…
- Trial name
- NCT00003464
- Testing
- temozolomide, radiation therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Duke University
Glioblastoma, Astrocytoma
Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)
The primary purpose of the study is to evaluate the efficacy and safety of temozolomide compared to semustine in the treatment of patients with glioblastoma multiforme or anaplastic astrocytoma.
- Trial name
- NCT00335075
- Testing
- Temozolomide, Semustine
- Volunteers
- 151 people
- Sponsor
- Merck Sharp & Dohme LLC
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating young patients with relapsed or refractory primary brain tumors or spinal cord tumors.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT01076530
- Testing
- vorinostat, temozolomide, diagnostic laboratory biomarker analysis
- Where
- 9 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
Phase 2, open-label study of nab-sirolimus in patients with recurrent high grade glioma following prior therapy and patients with newly diagnosed glioblastoma.
- Trial name
- NCT03463265
- Testing
- nab-sirolimus, nab-sirolimus + temozolomide, nab-sirolimus + bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- Aadi Bioscience, Inc.
Glioblastoma
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
This 2 arm study investigated the efficacy and safety of the addition of bevacizumab to the current standard of care (multimodality therapy of concurrent radiotherapy plus temozolomide followed by adjuvant temozolomide) as…
- Trial name
- NCT00943826
- Testing
- Bevacizumab, Temozolomide, Radiation therapy
- Where
- 133 sites in United States, Australia and 22 more
- Volunteers
- 921 people
- Sponsor
- Hoffmann-La Roche
Melanoma (Skin)
Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00568048
- Testing
- bevacizumab, temozolomide
- Where
- Switzerland
- Volunteers
- 62 people
- Sponsor
- Swiss Cancer Institute
Melanoma (Skin)
Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as interleukin-2 and interferon alfa stimulate a person's white blood cells to kill…
- Trial name
- NCT00014092
- Testing
- aldesleukin, recombinant interferon alfa, sargramostim
- Where
- 3 sites in United States
- Sponsor
- Saint Francis Hospital
Brain and Central Nervous System Tumors
Temozolomide in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have recurrent…
- Trial name
- NCT00004113
- Testing
- temozolomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center